
Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)
Achievement of the study’s primary endpoint, confirming glenzocimab’s very favorable safety profile Reduction in the number of intracerebral hemorrhages and